European Journal of Epidemiology

, Volume 28, Issue 8, pp 705–707 | Cite as

No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus

  • Paolo Pellegrino
  • Carla Carnovale
  • Valentina Perrone
  • Stefania Antoniazzi
  • Marco Pozzi
  • Emilio Clementi
  • Sonia Radice
Letter to the Editor

References

  1. 1.
    Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Gold MS, McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sex Health. 2010;7(3):320–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15(1):116–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry. 2011;82(11):1296–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J. 2007;26(11):979–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Paolo Pellegrino
    • 1
  • Carla Carnovale
    • 1
  • Valentina Perrone
    • 1
  • Stefania Antoniazzi
    • 1
  • Marco Pozzi
    • 2
  • Emilio Clementi
    • 1
    • 2
  • Sonia Radice
    • 1
  1. 1.Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital “Luigi Sacco”Università di MilanoMilanItaly
  2. 2.E. Medea Scientific InstituteLeccoItaly

Personalised recommendations